샘플 요청 목록

 카트 문의
시장보고서
상품코드
1513935

신장암 치료제 시장

Kidney Cancer Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 148 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신장암 치료제 세계 시장은 2030년까지 81억 달러에 달할 전망

2023년에 58억 달러로 추정된 신장암 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 4.8%로 성장해 2030년에는 81억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 표적 요법은 CAGR 5.2%로 성장을 지속하고, 분석 기간 종료 시 56억 달러에 달할 것으로 예측됩니다. 면역요법 분야의 성장률은 분석 기간 동안 CAGR 4.2%로 추정됩니다.

미국 시장은 16억 달러로 추정, 중국은 CAGR 8.2%로 성장 예측

미국 신장암 치료제 시장은 2023년 16억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 17억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 8.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.5%와 4.0%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계 신장암 치료제 시장 - 주요 동향과 촉진요인 요약

신장암은 치료에 대한 다양한 거동과 반응을 특징으로 하는 복잡한 질환이기 때문에 종양의 특이적인 특징에 기초한 미묘한 접근이 필요합니다. 초기 치료 전략은 조기 단계의 수술 개입부터 후기 단계의 고급 약리 치료에 이르기까지 다양한 암세포의 증식과 확산을 조절하도록 설계된 생물학적 요법과 표적 치료가 포함됩니다. 생물학적 요법은 특정 분자를 표적으로 함으로써 종양의 증식을 억제하고, 표적 요법은 암세포의 증식과 생존에 중요한 분자 표적에 초점을 맞춥니다. 이러한 첨단 치료법은 신장암의 치료 상황을 크게 바꾸어 많은 환자들에게 새로운 희망과 장기적인 통제 가능성을 제공합니다. 현재 진행중인 연구는 이러한 치료를 최적화하고, 그 효과를 높이고, 종합적인 치료 체계에 통합하는 것을 목표로 합니다.

진행된 신장암의 치료는 암 진행의 중요한 국면을 표적으로 하는 티로신 키나아제 억제제(TKI)와 면역요법에 의해 혁명적으로 변화했습니다. 수니티닙이나 파조파닙 등의 TKI는 암세포의 증식과 종양으로의 혈액 공급에 필수적인 효소를 저해하고, 종양의 기아 상태를 효과적으로 만들어 종양의 진전을 억제합니다. 니볼루맙과 같은 면역요법은 암세포가 면역시스템을 회피하는 능력을 파괴하고 암세포에 대한 신체의 자연면역반응을 강화합니다. 니볼루맙과 같은 약제와 이필리뮤맙이나 TKI 등의 다른 약제를 조합한 병용 요법의 개발은 치료 효과를 더욱 높여 진행 신장암 환자의 예후를 개선하는 것으로 증명되고 있습니다. 이러한 치료 전략은 환자와 건강 관리 제공업체들이 충분히 토론하고, 이익과 위험을 신중하게 검토하고, 새로운 치료법에 대한 접근을 제공하는 새로운 임상시험을 고려해야 합니다.

신장암 치료제 시장은 그 성장과 진화에 기여하는 여러 요인에 의해 견인되고 있습니다. 분자 생물학과 암 유전체 과학에 의해 박차를 가한 의약품 개발의 기술적 진보는 부작용이 적고, 보다 적은 효과적인 치료를 가능하게 하고, 환자나 종양의 특정한 유전자 프로파일에 맞춘 정밀의료로의 전환을 촉진합니다. 획기적인 치료제의 조기 승인과 희귀의약품의 우대 조치 등 규제 당국의 지원도 혁신적 치료의 신속한 소개를 뒷받침하고 있습니다. 의약품 개발에서 인공지능의 통합은 신약의 발견과 시험을 간소화하고 시간과 비용을 절감합니다. 제약 회사, 생명 공학 회사 및 학술 기관의 협력은 개발 파이프라인을 강화합니다. 또한 편리성이 높고 통원 횟수를 줄일 수 있는 외래암 치료에 대한 기호가 높아지고 있습니다. 환자의 지지와 의식의 향상이 조기 진단과 조기 치료로 이어지고, 경제 성장과 보험 적용의 향상이 고액이 되기 쉬운 새로운 치료법의 채용을 뒷받침하고 있습니다. 비만과 고혈압 증가 등 세계의 건강 동향은 효과적인 신장암 치료에 대한 수요를 더욱 높여 지속적인 혁신과 성장을 목표로 하는 역동적인 시장을 형성하고 있습니다.

조사 대상 기업 예(총 12건)

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.07.24

Global Kidney Cancer Drugs Market to Reach US$8.1 Billion by 2030

The global market for Kidney Cancer Drugs estimated at US$5.8 Billion in the year 2023, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$5.6 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.2% CAGR

The Kidney Cancer Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Kidney Cancer Drugs Market - Key Trends and Drivers Summarized

Kidney cancer, a complex disease characterized by variable behavior and response to treatments, requires a nuanced approach based on the specific characteristics of the tumor. Initial treatment strategies range from surgical interventions in early stages to advanced pharmacological treatments in later stages, including biological and targeted therapies designed to control the growth and spread of cancer cells. Biological therapies interfere with tumor growth by targeting specific molecules, while targeted therapies focus on molecular targets that are crucial for cancer cell proliferation and survival. These advanced therapies have significantly transformed the treatment landscape for kidney cancer, offering new hope and prolonged control over the disease for many patients. Ongoing research aims to optimize these treatments, enhancing their effectiveness and integrating them into comprehensive treatment regimes.

The treatment of advanced kidney cancer has been revolutionized by Tyrosine Kinase Inhibitors (TKIs) and immunotherapies that target critical aspects of cancer progression. TKIs, such as sunitinib and pazopanib, block enzymes essential for cancer cell growth and tumor blood supply, effectively starving and inhibiting tumor development. Immunotherapies like nivolumab disrupt cancer cells' ability to evade the immune system, enhancing the body’s natural immune response against cancer cells. The development of combination therapies, which pair drugs like nivolumab with other agents such as ipilimumab or TKIs, is proving to further enhance treatment efficacy, offering improved outcomes for patients with advanced kidney cancer. These treatment strategies necessitate thorough discussions between patients and healthcare providers to carefully weigh the benefits and risks, along with considerations for new clinical trials that offer access to emerging therapies.

The market for kidney cancer drugs is driven by multiple factors that contribute to its growth and evolution. Technological advances in drug development, spurred by molecular biology and cancer genomics, allow for more targeted and effective therapies with fewer side effects, fostering a shift towards precision medicine tailored to specific genetic profiles of patients and tumors. Regulatory support, including accelerated approvals for breakthrough therapies and incentives for orphan drugs, aids in the rapid introduction of innovative treatments. The integration of artificial intelligence in drug development streamlines the discovery and testing of new drugs, reducing time and cost. Collaborations among pharmaceutical companies, biotechnology firms, and academic institutions enhance the development pipeline. Moreover, there is an increasing preference for outpatient cancer therapies that offer convenience and reduce hospital visits. Patient advocacy and enhanced awareness lead to earlier diagnosis and treatment, while economic growth and better insurance coverage support the adoption of new, often costly, treatments. Global health trends, including rising obesity and hypertension rates, further drive the demand for effective kidney cancer treatments, shaping a dynamic market poised for continued innovation and growth.

Select Competitors (Total 12 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Kidney Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Kidney Cancer Propels Demand for Effective Treatment Options
    • Increasing Awareness and Early Diagnosis of Kidney Cancer Accelerates Market Penetration
    • Advances in Targeted Therapy and Immunotherapy Strengthen Business Case for Innovative Kidney Cancer Drugs
    • Focus on Personalized Medicine Drives Adoption of Precision Kidney Cancer Drugs
    • Growing Geriatric Population and Associated Cancer Risk Spurt Growth in Kidney Cancer Drugs Market
    • Introduction of Combination Therapies Throws the Spotlight on Enhanced Treatment Efficacy
    • Advances in Biomarker Identification Propel Development of Targeted Kidney Cancer Drugs
    • Focus on Minimizing Side Effects and Improving Quality of Life Sustains Demand for Innovative Drugs
    • Growing Adoption of Oral Chemotherapy Drugs Expands Treatment Options for Patients
    • Advances in Molecular Diagnostics Propel Growth in Precision Medicine for Kidney Cancer
    • Increasing Number of Clinical Trials and Pipeline Drugs Enhance Market Potential
    • Expansion of Telemedicine and Remote Patient Monitoring Drives Market Adoption
    • Focus on Patient-Centric Care Models Generates Demand for Personalized Kidney Cancer Treatments
    • Advances in Drug Delivery Systems Propel Development of Novel Kidney Cancer Therapies
    • Rising Prevalence of Lifestyle-Related Risk Factors Expands Addressable Market Opportunity
    • Development of Biosimilars and Generics Throws the Spotlight on Affordable Treatment Options
    • Increasing Focus on Integrative and Complementary Therapies Drives Demand for Holistic Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Angiogenesis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for mTOR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cytokine Immunotherapy (IL-2) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Kidney Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • JAPAN
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • CHINA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • EUROPE
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • FRANCE
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • GERMANY
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • INDIA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Kidney Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Kidney Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • AFRICA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제